N.J. drugmaker pulls in $125M from IPO

06/21/2013 | San Francisco Chronicle (free content) · Xconomy

PTC Therapeutics secured more than $125 million in an initial public offering and plans to use the proceeds to support research and development and for working capital. The New Jersey firm's lead drug candidate ataluren is designed to treat patients with genetic disorders caused by single-point mutations.

View Full Article in:

San Francisco Chronicle (free content) · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC